SIWA Therapeutics

SIWA Therapeutics Overview

Founded 2011
Status Private
Employees 4
Latest Deal Type Angel
Latest Deal Amount $6.37M
Latest Deal Amount

SIWA Therapeutics General Information


Operator of a pre-clinical stage company intended to emphases on a monoclonal antibody that targets and destroys cancerous cells. The company's first-in-class humanized monoclonal antibody ("mAb"), SIWA 318H, selectively targets both senescent cells ("SCs") and cancer cells for destruction by the immune system. It's In vivo results shows SIWA 318M (a SIWA 318H mouse homolog) reduces SCs in normally-aged, very old mice and reduces cancer metastasis lung foci (triple-negative breast cancer model). It can become the first comprehensive cancer therapy as it uniquely reduces cancer cells as well as the SCs surrounding the cancer cells in the tumor micro-environment that stimulate, feed, and protect them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Drug Discovery
Drug Delivery
Discovery Tools (Healthcare)
Primary Office
  • 1231 Merchandise Mart
  • Chicago, IL 60654
  • United States
+1 (312) 000-0000

SIWA Therapeutics Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SIWA Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 13-Aug-2019 $6.37M 000 Completed Pre-Clinical Trials
2. Angel (individual) 22-May-2017 00.000 00.000 Completed Pre-Clinical Trials
1. Capitalization 01-Jan-2011 Completed Startup

SIWA Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Lewis Gruber Co-Founder, Chief Executive Officer & Chief Scientific Officer
Jim Alvarez Chief Operating Officer & Board Member
Misty Gruber Co-Founder & Chief Administrative Officer

SIWA Therapeutics Board Members (3)

Name Representing Role Since
Alex Kormushoff SIWA Therapeutics Board Member 000 0000
Jim Alvarez SIWA Therapeutics Chief Operating Officer & Board Member 000 0000
John Peters III SIWA Therapeutics Chairman 000 0000

Ready to get started?

Request a free trial